Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea

Dec 17, 2025Current opinion in endocrinology, diabetes, and obesity

Tirzepatide’s potential benefits for obstructive sleep apnea beyond weight loss

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Tirzepatide has demonstrated significant reductions in apnea-hypopnea index (AHI) among patients with obstructive sleep apnea and obesity.

Tirzepatide is the first medication approved by the FDA specifically for moderate-to-severe obstructive sleep apnea in adults with obesity.
In addition to improving sleep apnea outcomes, tirzepatide is associated with weight loss.
The medication may also reduce cardiovascular, liver, and kidney events.
Tirzepatide could represent a promising therapy for obstructive sleep apnea, potentially offering benefits beyond traditional treatments.

AI simplified

PURPOSE OF REVIEW: This review summarizes emerging evidence on the use of the dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide in improving obstructive sleep apnea (OSA) outcomes in individuals with obesity.

RECENT FINDINGS: Tirzepatide has demonstrated significant reductions in apnea-hypopnea index (AHI) among patients with OSA and coexisting obesity. It has recently become the first medication approved by the U.S. Food and Drug Administration (FDA) specifically for moderate-to-severe OSA in adults with obesity. In addition to weight loss, tirzepatide has been associated with reduced cardiovascular, hepatic, and renal events, suggesting broader systemic benefits.

SUMMARY: As a dual GIP/GLP-1 RA, tirzepatide represents a promising therapy for OSA in individuals with obesity, offering benefits of both weight reduction and symptom improvement. Given the high burden and underdiagnosis of OSA, particularly in populations with obesity, it should be considered earlier in the treatment algorithm, either in combination with or as an alternative to traditional therapies.

Full Text

Full text is available at the source.

View full text ↗

Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief